Partnerships -
Current Partnerships
Xytis has established
partnerships and relationships with leading healthcare
companies, contract research organization and academic
institutions such as:
 |
In June 2005, Xytis and Fournier entered
into a license agreement for the development
and commercialization of
XY2405, a potential
new medication for the treatment of
traumatic brain injury, originating from
Fournier Pharma’s Research. |
|
|
Fournier Pharma has
granted Xytis an exclusive worldwide license for
the development, manufacture and sale of the
product containing its bradykinin B2 antagonist
for traumatic brain injury and possibly other
indications. In July 2006, Fournier Pharma also
granted Xytis exclusive rights to manufacture
the compound. Fournier Pharma was later acquired
by Solvay, with who Xytis maintains an excellent
collaboration .
|
|
 |
In January 2005, Xytis and Rottapharm
S.P.A. entered into a license agreement
for the development and
commercialization of
XY2401, a potential
new psychotropic medication for the
treatment of a variety of disorders. Xytis has acquired an exclusive
license to develop and market the compound in
the United States, Canada, Japan, Australia and
New Zealand, while Rottapharm retains rights in
the rest of the world.
|
|
| |
|
 |
In September 2006, Xytis signed a
Collaborative Research and Development Agreement
(CRADA) to test the hypothesis that
XY2401 can
ameliorate cocaine addiction. Under the term of the
agreement, safety studies evaluating the interaction
of cocaine and XY2401 in animals and humans are
conducted by the National Institute of Drug Abuse
(NIDA).
|
|
 |
Forenap Pharma is an international
Contract Research Organisation (CRO) currently
conducting the phase I trials on
XY2401 for Xytis.
|
|
 |
Xytis collaborates closely with
Professor Kelvin W. Gee, professor of Pharmacology at UC Irvine. Kelvin has pioneered work in neuropharmacology, he has more than 20 years experience in the discovery of allosteric modulators of GABAA receptors and other ligand gated ion channels. |
|
The discovery group, supported by Xytis grants to Kelvin’s lab, invented XY1029, XY2411, XY2412 and XY4083 and is developing backups and improvements to these lead molecules. Kelvin, who is a serial biotechnology entrepreneur , started his first company, CoCensys, in 1989. He continues to counsel academic entrepreneurs and pursue academic life. He provides a tremendous support to Xytis business development activities.
|
|
